Provided by Tiger Trade Technology Pte. Ltd.

ASCLETIS-B

4.695
-0.145-3.00%
Volume:2.41M
Turnover:11.31M
Market Cap:4.94B
PE:-12.69
High:4.860
Open:4.700
Low:4.580
Close:4.840
52wk High:19.860
52wk Low:4.115
Shares:1.05B
HK Float Shares:1.05B
Volume Ratio:1.16
T/O Rate:0.23%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.370
ROE:-28.59%
ROA:-19.64%
PB:1.85
PE(LYR):-12.69
PS:4438.37

Loading ...

Ascletis Pharma Submits Investigational New Drug Application to US FDA for Obesity Drug

MT Newswires Live
·
Nov 11

Ascletis Submits IND Application to US FDA for Asc30_39 FDC

Reuters
·
Nov 11

Ascletis Files U.S. IND for ASC30_39, a First-in-Class Oral GLP-1R/Amylin Combination Targeting Obesity

Bulletin Express
·
Nov 11

Ascletis Submits Ind Application to the U.S. FDA for Asc30_39 Fdc, a Potentially First-in-Class Oral Small Molecule Fixed-Dose Combination of Glp-1R Agonist and Selective Amylin Receptor Agonist, for the Treatment of Obesity

THOMSON REUTERS
·
Nov 11

Ascletis Pharma - Submits Ind Application to U.S. FDA for Asc30_39 Fdc for Obesity

THOMSON REUTERS
·
Nov 11

Ascletis Pharma-B Repurchases 200,000 Shares for HK$960,600 on November 5

Stock News
·
Nov 05

Ascletis Pharma Files HKEX Return Announcing Share Buyback for Cancellation

Reuters
·
Nov 05

Ascletis Issues 1.80 Million Employee Stock Options, Setting HK$4.923 Exercise Price

Bulletin Express
·
Nov 04

Ascletis Pharma-B Grants 1.8 Million Share Options

Stock News
·
Nov 04

Ascletis-B Keeps October Share Base Steady; 5.50 Million Repurchased Shares Await Cancellation

Bulletin Express
·
Nov 04

Hong Kong Stock Movers: Innovative Drug Concept Stocks Extend Losses, GENSCRIPT B-1K (01548) Plunges Over 15%, KEYMED BIO-B (02162) Drops Nearly 5%

Stock News
·
Nov 03

Ascletis Pharma Files HKEX Next Day Disclosure Return on Share Buyback for Cancellation

Reuters
·
Oct 30

Ascletis Pharma-B Repurchases 100,000 Shares for Approximately HK$525,400 on October 29

Stock News
·
Oct 29

Hong Kong Stock Announcement Highlights: Ping An's First Three Quarters Net Profit Attributable to Shareholders Reaches 96.645 Billion Yuan, Continues to Deepen "Comprehensive Finance + Healthcare and Elderly Care" Dual-Wheel Parallel, Technology-Driven Strategy

Stock News
·
Oct 29

Ascletis Pharma-B (01672) Reports Oral GLP-1 Candidate ASC30 Achieves 1.7% Placebo-Adjusted HbA1c Reduction at Week 12 in U.S. Phase II Diabetes Trial

Stock News
·
Oct 29

Ascletis' ASC30 Cuts HbA1c by up to 1.7% Versus Placebo in Phase II Diabetes Trial

Reuters
·
Oct 29

Ascletis Highlights Robust U.S. Phase II Data for Oral GLP-1 Candidate ASC30; Demonstrates 1.7% Placebo-Adjusted HbA1c Decline at 12 Weeks

Bulletin Express
·
Oct 29

Ascletis' Oral Small Molecule Glp-1, Asc30, Demonstrated Placebo-Adjusted Hba1c Reduction of 1.7% at 12 Weeks from Its U.S. Phase Ii Study in Participants with Diabetes

THOMSON REUTERS
·
Oct 29

Ascletis Pharma Reports 5.10 Million-Share Buy-Back; HKD 37.87 Million Spent Since June

Bulletin Express
·
Oct 27

Ascletis Pharma Repurchases 100,000 Shares for About HK$558,800 on October 26

Stock News
·
Oct 26